SH-SY5Y, as in vitro modules, are a promising choice for examining the therapeutic effects of medicines on modulation of APP processing and A-induced AD pathogenesis, but this model restricts the study of other hypotheses and molecular targets accountable for AD pathogenesis. This evidence concerns the gene APP and Alzheimer disease.